19:00 , Jan 4, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: December 2017

New Therapeutic Targets and Biomarkers: December 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during December 2017. Therapeutic targets are defined as any protein, gene or other...
00:20 , Dec 22, 2017 |  BC Innovations  |  Product R&D

Dengvaxia’s warning

The fallout of Sanofi’s dengue vaccine debacle has researchers scrambling to rationalize whether competitor products will fall afoul of the same effects, and whether other, related fields should change course. The early upshot is that...
19:58 , Sep 26, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Zika virus Cell culture and mouse studies suggest mAbs against DENV_gp1 could help treat Zika infection. In infected monkey kidney epithelial cells, a mAb against DENV_gp1 neutralized two strains of Zika virus with EC...
23:48 , Feb 28, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers IgG antibodies with high affinity for FCGR3A could help predict the severity of dengue fever. Fifteen patients with dengue virus infection who developed dengue hemorrhagic fever or dengue shock syndrome had higher...
07:00 , Jun 2, 2016 |  BC Innovations  |  Translation in Brief

Double duty in dengue

Inhibitors of BCR-ABL tyrosine kinase (BCR-ABL) , better known for treating chronic myelogenous leukemia (CML), might provide new opportunities for preventing and treating dengue fever. A group from Harvard Medical School and Dana-Farber Cancer Institute...
07:00 , May 26, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: BCR-ABL tyrosine kinase (BCR-ABL); dengue virus envelope protein E (DENV_gp1)

Infectious disease INDICATION: Dengue fever Cell culture studies identified dual inhibitors of BCR-ABL and DENV_gp1 that could help treat dengue infection. Previous studies in dengue virus-infected hamster kidney fibroblasts identified an allosteric inhibitor of BCR-ABL...
07:00 , Aug 27, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Structural analysis of a human mAb-dengue virus envelope protein E (DENV_gp1) complex for vaccine design

Drug platforms TECHNOLOGY: Structural analyses dengue virus envelope protein E (DENV_gp1) National University of Singapore Vanderbilt University...
07:00 , Aug 13, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Dengue virus envelope protein E (DENV_gp1)

Infectious disease INDICATION: Dengue fever; viral infection Mouse studies suggest intramuscular delivery of DNA vectors encoding human neutralizing antibodies could help prevent dengue fever and viral infections. A DNA vector was constructed containing IgG heavy...
07:00 , Aug 6, 2015 |  BC Innovations  |  Product R&D

Impede a fever

A team at the Massachusetts Institute of Technology has developed an antibody that could treat dengue infections caused by all four serotypes of the virus, and might be able to prevent the disease as well....
07:00 , Jul 23, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Dengue virus envelope protein E (DENV_gp1)

Infectious disease INDICATION: Dengue fever In vitro and mouse studies suggest a mAb against DENV_gp1 could help treat infections by all four dengue serotypes. Antibodies elicited by previous infections with one dengue serotype can exacerbate...